Medical Device Global Market Access

This episode details the mandatory requirement for foreign medical device manufacturers to appoint a Singapore Registrant. We explain the role and responsibilities of this local authorized representative as required by the Health Sciences Authority (HSA), the strategic implications of choosing a representative, and how it impacts market access for Class B, C, and D devices. - What is a Singapore R...

This episode provides a detailed guide to the Singapore Health Sciences Authority (HSA) medical device registration pathways for Class B, C, and D devices. We explore the four main evaluation routes—Full, Abridged, Expedited, and Immediate—and explain how leveraging prior approvals from key international reference agencies like the US FDA and EU Notified Bodies can significantly accelerate your pr...

This episode provides a detailed guide to Singapore's Health Sciences Authority (HSA) medical device risk classification system. We explore the four-tier structure (Class A to Class D), explain how it aligns with international GHTF/IMDRF principles, and discuss how factors like intended use and invasiveness determine a device's class. Understanding this foundational step is crucial as it dictates...

This episode provides a detailed overview of Singapore's medical device registration framework. We cover the role of the Health Sciences Authority (HSA), the foundational Health Products Act 2007 and Medical Devices Regulations 2010, the four-tiered risk classification system, and the various registration pathways available to manufacturers based on prior approvals in reference markets. - What is...

This episode provides a detailed overview of the regulatory requirements for medical device labeling, Instructions for Use (IFU), and Spanish translation for market entry into Colombia. We explore the specific rules set by the national authority, INVIMA, and explain how these elements are meticulously evaluated during the registration process to ensure patient safety and device efficacy. - What is...

This episode provides a detailed breakdown of the costs associated with registering a medical device in Colombia with the regulatory authority, INVIMA. We cover the official government application fees based on risk classification, as well as essential ongoing costs such as renewals, modification fees, and the expenses related to local representation and translation services, giving you a complete...

This episode explores the requirements for medical device registration in Colombia, focusing on whether prior approval from a reference country like the US or EU is mandatory. We detail the role of a Certificate of Free Sale (CFS), the different regulatory pathways defined by INVIMA based on device risk classification (Class I, IIa, IIb, III), and the specific process available for novel devices t...

This episode provides a detailed guide on the essential documents required for medical device registration in Colombia through the regulatory body, INVIMA. We cover the critical importance of the Certificate of Free Sale (CFS), the specific requirements for legalization and apostilles, the necessity of a local legal representative, and the comprehensive components of the technical file, including...

This episode explores the medical device registration process in Colombia, focusing on the timelines set by the regulatory authority, INVIMA. We break down the key differences between the standard (controlled) review pathway for high-risk devices and the expedited (automatic) process for lower-risk devices, including eligibility requirements and realistic time-to-market estimates for each. This is...

This episode details the mandatory requirement for a local authorized representative for medical device registration in Colombia. We explore the legal responsibilities this representative assumes as stipulated by the regulatory authority, INVIMA, under Decree 4725 of 2005. The discussion covers their central role in registration, post-market surveillance (technovigilance), and communication with a...

This episode provides a detailed overview of Colombia's medical device risk classification system as regulated by INVIMA under Decree 4725 of 2005. We explain the four-tiered risk classes (Class I, IIa, IIb, and III), the criteria used for classification such as invasiveness and duration of use, and how a device's class determines its regulatory pathway for market approval in this key Latin Americ...

This episode provides a comprehensive guide for foreign medical device manufacturers on registering their products in Colombia. We cover the role of the regulatory authority, INVIMA, the risk-based device classification system, and the essential documentation required for a successful submission, including the Certificate of Free Sale (CFS) and ISO 13485 certification. The host details the distinc...

This episode breaks down the critical responsibilities of Economic Operators—Manufacturer, Authorised Representative, Importer, and Distributor—and the Person Responsible for Regulatory Compliance (PRRC) under the EU's MDR and IVDR. We explore the common operational pitfalls, such as role confusion, misaligned contracts, and PRRC coverage gaps, that frequently lead to audit findings and can jeopar...

This episode explores the growing tension between single-use medical devices and the push for sustainability. We delve into the complex world of reprocessing, examining the regulatory hurdles, validation requirements, and critical liability shifts under frameworks like the US FDA and the EU's Medical Device Regulation (MDR). We discuss how this trend impacts manufacturers, from Instructions for Us...

This episode details the significant regulatory complexities for Companion Diagnostics (CDx) under the European Union's In Vitro Diagnostic Regulation (IVDR). We explore why these devices are now in a higher risk class, the impact of mandatory consultations with medicinal authorities like the EMA, and the critical need for seamless coordination between IVD manufacturers and their pharmaceutical pa...

This episode demystifies the requirements for In-Vitro Diagnostic (IVD) performance studies under the EU's IVDR. We explore the crucial guidance document, MDCG 2025-5, published in June 2024, to clarify common points of confusion for manufacturers. We cover the key differences between study notifications and applications, what constitutes a 'substantial modification,' the rules for using leftover...

This episode provides a detailed breakdown of the three pillars of performance evaluation required under the EU's In Vitro Diagnostic Regulation (IVDR): scientific validity, analytical performance, and clinical performance. We focus specifically on the heightened requirements and common pitfalls for manufacturers of high-risk Class C and D devices, explaining why underestimating the clinical evide...

This episode delves into the critical requirements for medical device cybersecurity in the European Union. We explore the concept of "state of the art" as defined by the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), focusing on the key guidance document, MDCG 2019-16 Rev. 1. Learn how this guidance impacts your design controls, risk management, post-market surveilla...

This episode explores the critical intersection of the new European Union AI Act and the existing Medical Device and In-Vitro Diagnostic Regulations (MDR/IVDR). We unpack the challenges of dual compliance for manufacturers of AI-enabled medical devices and explain how the recent joint guidance from the Medical Device Coordination Group and the Artificial Intelligence Board (MDCG 2025-6 / AIB 2025-...

This episode explores the critical new regulatory focus from Europe's Medical Device Coordination Group (MDCG) on Software as a Medical Device (SaMD) distributed via online platforms. We discuss how the concept of 'making available on the market' now directly applies to app stores, forcing manufacturers to integrate platform listings, version control, and geographic restrictions into their core co...

This episode delves into the critical definition of a "significant change" for legacy medical devices and IVDs under the EU MDR and IVDR. We explore the official MDCG guidance, outlining what types of modifications can end a device's transitional grace period, forcing an early and costly move to full certification. Learn about the high-stakes impact on market access and the importance of a robust...

This episode delves into the complex realities of Unique Device Identification (UDI) strategy for medical devices. The host explores common blockers that go beyond simple barcode generation, including the nuanced rules for UDI assignment across different packaging configurations, the challenges of carrier placement, and the critical importance of database submission readiness for platforms like EU...

This episode explores the critical operational hotspots in medical device vigilance under regulations like the EU MDR. We examine the pressures for faster, higher-quality incident investigations, the complexities of making accurate MDR reportability decisions, and the nuances of establishing effective trend reporting thresholds. Discover how these vigilance activities are directly linked to your C...

This episode explores the critical shift in regulatory focus from Post-Market Surveillance (PMS) planning to execution. We discuss why Notified Bodies and regulators, particularly under the EU MDR, are no longer accepting PMS and Post-Market Clinical Follow-up (PMCF) as a paperwork exercise. Learn about the concept of a “silent nonconformity” and how a weak, poorly executed surveillance strategy c...

This episode delves into the stringent clinical evidence requirements under the European Union's Medical Device Regulation (MDR 2017/745). We explore the top challenges manufacturers face, including the heightened standards for clinical evaluation plans and reports (CEPs/CERs), the complexities of justifying 'sufficient data,' the difficulties in making equivalence arguments, and the continuous na...